Takeda Canada Inc. Concludes Letter of Intent (LOI) with the Pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY (Maribavir) for the Treatment of Adults with a Post-Transplant Cytomegalovirus (CMV) Infection
Portfolio Pulse from Benzinga Newsdesk
Takeda Canada Inc. has concluded a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY (maribavir) to treat adults with post-transplant cytomegalovirus (CMV) infection. This agreement allows provinces and territories to start listing LIVTENCITY in their formularies.
May 16, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Takeda Canada Inc. has finalized an LOI with the pCPA for LIVTENCITY, enabling provinces and territories to list the drug in their formularies. This could lead to increased sales and market penetration in Canada.
The completion of the LOI with the pCPA is a significant step for Takeda, as it allows for the listing of LIVTENCITY in provincial and territorial formularies. This could lead to increased sales and market penetration in Canada, positively impacting Takeda's revenue.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80